A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Clinical trial NCT07283640 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07283640
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-11-18
- Primary completion
- 2029-08-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.